Â鶹Íø

Principal Investigator/s: Professor Damian Downey

Name of the Study: CLEAR

Why is this Study important?

PsA is the predominant pathogen associated with frequent respiratory infections in bronchiectasis patients. Bronchiectasis patients colonized with PsA experience more severe respiratory symptoms, reduced quality of life, greater airflow obstruction, an increased risk of hospitalization, and higher mortality rates. The trial drug AZD0292 is designed to help the body’s immune system recognize and destroy PsA. Researchers believe AZD0292 could help reduce exacerbations in people who have bronchiectasis and chronic PsA colonization.

What is the Research question/aim?:

This Phase IIb study aims to assess the efficacy, safety, and PK of 2 dosage regimens of  AZD0292 administered IV every 4 weeks, as an add-on to SoC treatment, in participants 12 years of age and older as compared to placebo.

What the Study involves:

The study will consist of 3 periods: a 5-week screening period, a variable duration treatment  period of 24 to 48 weeks (efficacy observational period of 28 to 52 weeks, which includes the variable treatment time + 4 additional weeks after the last dose), and a 24-week safety followup period post last dose.

Who can take part in the Study?

Participants 12 years of Age and Older with non-CF and CF Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

Contact Information:

Abitha Nair 02895040342

Abitha.nair@belfasttrust.hscni.net

NICRF

U Floor

Belfast City Hospital

51a Lisburn Road

Belfast

BT9 7AB